Massimo Cristofanilli, MD, Northwestern University
Articles by Massimo Cristofanilli, MD, Northwestern University
Treatment Advances in HR+ Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.
Case Discussion 2: Systemic Therapy for ER+, PR+, HER2- Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University Breast oncologists review the appropriateness for treating a patient with ER-positive, PR-positive, HER2-negative breast cancer with systemic therapy, with special considerations regarding sequencing therapy if using a CDK4/6 inhibitor as adjuvant therapy.
The PRIME II Study in HR+ Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University Andrew Seidman, MD, comments on results of the PRIME II study presented at SABCS and the appropriateness for radiation therapy in certain patient populations with HR-positive breast cancer.
The PENELOPE-B Study in HR+ Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University Dr Massimo Cristofanilli, of the Feinberg School of Medicine, describes the PENELOPE-B study of palbociclib and endocrine therapy for patients with HR-positive breast cancer at high risk of relapse after neoadjuvant chemotherapy.
Updated Results of MonarchE in HR+ Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University Dr Sara Tolaney comments on recent updates of the monarchE trial of abemaciclib and adjuvant endocrine therapy for high-risk early stage breast cancer as presented at SABCS 2020.
Rationale for Ovarian Suppression in HR+ Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University During a discussion regarding data demonstrated by the RxPONDER trial in HR-positive breast cancer, breast oncologists consider when ovarian suppression is most appropriate and for whom.
Results of RxPONDER in HR+ Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University Dr Andrew Seidman reacts to outcomes of the RxPONDER trial of chemotherapy use in women with HR-positive breast cancer at low risk of recurrence.
Early-Stage HR+ Breast Cancer: Treatment Options
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
Risk of Recurrence in Early-Stage HR+ Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
HR+ MBC: Resistance to CDK4/6 Inhibitors
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
Targeting the PI3K/AKT/mTOR Pathway in HR+ MBC
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
Treating HR+ MBC After Frontline CDK4/6 Therapy
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
Treating PIK3CA Mutations in HR+ MBC
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
Case Discussion 1: Resistance to a CDK4/6 Inhibitor
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
CDK4/6 Inhibitors for HR+ MBC: Data and Utilization
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
Frontline Therapy for HR+ MBC: CDK4/6 Inhibitors
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University 
Evaluating Tumor Biology in HR+ Metastatic Breast Cancer
BySara A. Hurvitz, MD, David Geffen School of Medicine,Massimo Cristofanilli, MD, Northwestern University,Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center,Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Treating PIK3CA Mutations in HR+ MBC
HR+ MBC: Resistance to CDK4/6 Inhibitors
CDK4/6 Inhibitors for HR+ MBC: Data and Utilization
The PRIME II Study in HR+ Breast Cancer
Targeting the PI3K/AKT/mTOR Pathway in HR+ MBC
Case Discussion 1: Resistance to a CDK4/6 Inhibitor